000513 丽珠集团
已收盘 02-11 15:00:00
资讯
新帖
简况
每周股票复盘：丽珠集团（000513）为子公司提供9.1亿元担保
证券之星 · 02-08
每周股票复盘：丽珠集团（000513）为子公司提供9.1亿元担保
丽珠集团（000513）披露为子公司提供担保进展公告，2月4日股价上涨1.4%
证券之星 · 02-04
丽珠集团（000513）披露为子公司提供担保进展公告，2月4日股价上涨1.4%
丽珠集团（000513）披露证券变动月报表，2月2日股价下跌1.2%
证券之星 · 02-02
丽珠集团（000513）披露证券变动月报表，2月2日股价下跌1.2%
【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3只个股（附名单）
证券之星 · 01-23
【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3只个股（附名单）
丽珠集团：丽珠生物拥有三大业务板块
证券日报网 · 01-22
丽珠集团：丽珠生物拥有三大业务板块
每周股票复盘：丽珠集团（000513）回购股份注销完成
证券之星 · 01-11
每周股票复盘：丽珠集团（000513）回购股份注销完成
丽珠集团最新公告：莱康奇塔单抗注射液被纳入优先审评审批程序
证券之星 · 01-07
丽珠集团最新公告：莱康奇塔单抗注射液被纳入优先审评审批程序
丽珠集团（000513）披露关于回购A股股份注销完成暨股份变动公告，1月5日股价上涨2.0%
证券之星 · 01-05
丽珠集团（000513）披露关于回购A股股份注销完成暨股份变动公告，1月5日股价上涨2.0%
丽珠集团旗下新友贸海斥资1500万元认购毛毛伙伴增资
美股速递 · 2025-12-30
丽珠集团旗下新友贸海斥资1500万元认购毛毛伙伴增资
丽珠集团(000513.SZ)：莱康奇塔单抗注射液上市许可申请获受理
智通财经 · 2025-12-24
丽珠集团(000513.SZ)：莱康奇塔单抗注射液上市许可申请获受理
丽珠集团 - 乐卡奴单抗注射液的上市许可申请已获中国Nmpa接受审查
美股速递 · 2025-12-24
丽珠集团 - 乐卡奴单抗注射液的上市许可申请已获中国Nmpa接受审查
丽珠集团（000513）披露获得药物临床试验批准通知书，12月22日股价下跌0.14%
证券之星 · 2025-12-22
丽珠集团（000513）披露获得药物临床试验批准通知书，12月22日股价下跌0.14%
丽珠集团最新公告：子公司NS-041片新增适应症获批开展临床试验
证券之星 · 2025-12-21
丽珠集团最新公告：子公司NS-041片新增适应症获批开展临床试验
丽珠集团（000513）披露调整与丽珠单抗2025年度持续关连交易预计，12月8日股价下跌0.08%
证券之星 · 2025-12-08
丽珠集团（000513）披露调整与丽珠单抗2025年度持续关连交易预计，12月8日股价下跌0.08%
丽珠集团(000513.SZ)：公司2025年共有194个产品纳入国家医保目录
智通财经 · 2025-12-08
丽珠集团(000513.SZ)：公司2025年共有194个产品纳入国家医保目录
丽珠集团（000513）披露关于回购公司股份的进展公告，12月01日股价上涨1.24%
证券之星 · 2025-12-01
丽珠集团（000513）披露关于回购公司股份的进展公告，12月01日股价上涨1.24%
【机构调研记录】易米基金调研丽珠集团、众生药业
证券之星 · 2025-12-01
【机构调研记录】易米基金调研丽珠集团、众生药业
每周股票复盘：丽珠集团（000513）拟变更独立董事并召开临时股东大会
证券之星 · 2025-11-16
每周股票复盘：丽珠集团（000513）拟变更独立董事并召开临时股东大会
丽珠集团（000513）披露独立董事候选人取得独立董事培训证明，11月13日股价上涨0.19%
证券之星 · 2025-11-13
丽珠集团（000513）披露独立董事候选人取得独立董事培训证明，11月13日股价上涨0.19%
丽珠集团（000513）披露拟取消监事会并修订公司章程，11月10日股价上涨0.29%
证券之星 · 2025-11-10
丽珠集团（000513）披露拟取消监事会并修订公司章程，11月10日股价上涨0.29%
加载更多
公司概况
公司名称：
丽珠医药集团股份有限公司
所属行业：
医药制造业
上市日期：
1993-10-28
主营业务：
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是消化道产品、促性激素产品、精神产品、抗感染及其他产品、原料药及中间体产品、中药制剂产品、生物制品、诊断试剂及设备产品、其他。
发行价格：
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":35.47,"timestamp":1770793380000,"preClose":35.59,"halted":0,"volume":2926922,"delay":0,"changeRate":-0.0034,"floatShares":568000000,"shares":888000000,"eps":2.413,"marketStatus":"已收盘","change":-0.12,"latestTime":"02-11 15:00:00","open":35.51,"high":35.65,"low":35.45,"amount":104000000,"amplitude":0.0056,"askPrice":35.48,"askSize":72,"bidPrice":35.47,"bidSize":67,"shortable":0,"etf":0,"ttmEps":2.413,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770859800000},"marketStatusCode":5,"adr":0,"adjPreClose":35.59,"symbolType":"stock","openAndCloseTimeList":[[1770773400000,1770780600000],[1770786000000,1770793200000]],"highLimit":39.15,"lowLimit":32.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":887907171,"isCdr":false,"pbRate":2.26,"roa":"--","peRate":14.699544,"roe":"12.49%","epsLYR":2.24,"committee":0.251838,"marketValue":31494000000,"turnoverRate":0.0052,"status":1,"hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":29.6,"timestamp":1770795566374,"preClose":29.5,"halted":0,"volume":895650,"delay":0,"premium":"-26.22"},"floatMarketCap":20145000000},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2609525337","title":"每周股票复盘：丽珠集团（000513）为子公司提供9.1亿元担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525337","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525337?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:46","pubTimestamp":1770486374,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，丽珠集团报收于35.46元，较上周的34.96元上涨1.43%。本周关注点公司公告汇总：丽珠集团为子公司丽珠合成和丽珠单抗提供合计9.1亿元担保。公司公告汇总H股公告：证券变动月报表丽珠医药集团股份有限公司提交截至2026年1月31日的证券变动月报表，显示公司H股和A股的法定/注册股本及已发行股份均无变动。公司对丽珠单抗持股66.54%，其年度担保上限为21亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0187","BK0239"],"gpt_icon":0},{"id":"2608607013","title":"丽珠集团（000513）披露为子公司提供担保进展公告，2月4日股价上涨1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608607013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608607013?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:22","pubTimestamp":1770214940,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，丽珠集团报收于35.49元，较前一交易日上涨1.4%，最新总市值为315.12亿元。近日，丽珠医药集团股份有限公司披露《关于为子公司提供担保的进展公告》。公告显示，公司于2026年1月为全资子公司丽珠合成和控股子公司丽珠单抗提供担保。公司对丽珠单抗持股66.54%，其年度担保上限为21亿元。截至2026年1月31日，公司对外担保余额为174,476.12万元，占归属于母公司净资产的12.59%，均为对子公司的担保，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0187","BK0239"],"gpt_icon":0},{"id":"2608860194","title":"丽珠集团（000513）披露证券变动月报表，2月2日股价下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608860194?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:53","pubTimestamp":1770043995,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，丽珠集团报收于34.54元，较前一交易日下跌1.2%，最新总市值为306.68亿元。该股当日开盘34.81元，最高35.11元，最低34.47元，成交额达2.3亿元，换手率为1.16%。近日，丽珠医药集团股份有限公司披露截至2026年1月31日的证券变动月报表。公告显示，公司H股和A股的法定/注册股本及已发行股份均无变动。A股于深圳证券交易所上市，股份代号000513，上月底结存及本月底结存均为588,100,054股，每股面值人民币1元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK0028","000513","BK0188","BK0239","BK0187"],"gpt_icon":0},{"id":"2605948446","title":"【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2605948446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605948446?lang=zh_cn&edition=full","pubTime":"2026-01-23 08:12","pubTimestamp":1769127128,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月22日披露的机构调研信息，宝盈基金近期对3家上市公司进行了调研，相关名单如下：1）丽珠集团 个股亮点：公司已正式完成DeepSeek-R1 671B“满血”版的部署应用，成为国内首批将千亿参数级AI模型引入核心业务的医药企业2）ST绝味 调研纪要：公司现处于“其他风险警示”期间，将在中国证监会处罚决定满12个月且完成财务追溯重述后，申请撤销风险警示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300005860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0238","BK0187","BK0028","BK0239","603517"],"gpt_icon":0},{"id":"2605498879","title":"丽珠集团：丽珠生物拥有三大业务板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2605498879","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605498879?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:08","pubTimestamp":1769080080,"startTime":"0","endTime":"0","summary":"证券日报网1月22日讯，丽珠集团在接受调研者提问时表示，丽珠生物是健康元和丽珠集团共同唯一的生物药平台，拥有三大主要业务板块：自免领域、生殖领域和疫苗领域。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260122/c674231665.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260122/c674231665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0028","000513","BK0187","BK0188","BK0239"],"gpt_icon":0},{"id":"2602353988","title":"每周股票复盘：丽珠集团（000513）回购股份注销完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2602353988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602353988?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:25","pubTimestamp":1768076709,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，丽珠集团报收于36.58元，较上周的34.46元上涨6.15%。本周，丽珠集团1月7日盘中最高价报37.42元。本周关注点公司公告汇总：丽珠集团完成回购A股股份注销，共注销16,193,259股，占注销前总股本的1.79%。本次注销后，公司已发行A股股份总数由604,293,313股减少至588,100,054股。H股公告：证券变动月报表丽珠医药集团股份有限公司截至2025年12月31日，普通股H股法定/注册股本无变动，普通股A股因购回股份减少16,193,259股，导致法定/注册股本相应减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0239","BK0187"],"gpt_icon":0},{"id":"2601147879","title":"丽珠集团最新公告：莱康奇塔单抗注射液被纳入优先审评审批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601147879","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601147879?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:50","pubTimestamp":1767779411,"startTime":"0","endTime":"0","summary":"丽珠集团公告，公司控股子公司珠海市丽珠单抗生物技术有限公司与北京鑫康合生物医药科技有限公司联合开发的产品莱康奇塔单抗注射液已纳入优先审评品种名单，正式进入药品上市许可优先审评审批程序。拟定适应症（或功能主治）：本品用于适合接受系统治疗或光疗的中重度斑块状银屑病成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700028084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0239","BK0187"],"gpt_icon":0},{"id":"2601363007","title":"丽珠集团（000513）披露关于回购A股股份注销完成暨股份变动公告，1月5日股价上涨2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363007?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:47","pubTimestamp":1767606473,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，丽珠集团报收于35.15元，较前一交易日上涨2.0%，最新总市值为312.1亿元。公司近日发布公告称，丽珠医药集团股份有限公司已完成回购A股股份的注销工作，共注销16,193,259股，占注销前总股本的1.79%，实际回购金额为600,217,787.75元。注销后公司总股本由904,100,430股减少至887,907,171股。本次注销符合相关法规要求，股权分布仍符合上市条件。因总股本减少，控股股东健康元及其一致行动人持股比例被动上升，合计持股由46.33%增至47.18%，未发生股份变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500026283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","159982","399300","BK0188","BK0187","BK0239"],"gpt_icon":0},{"id":"1195202041","title":"丽珠集团旗下新友贸海斥资1500万元认购毛毛伙伴增资","url":"https://stock-news.laohu8.com/highlight/detail?id=1195202041","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195202041?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:32","pubTimestamp":1767090736,"startTime":"0","endTime":"0","summary":"丽珠集团宣布，其关联企业新友贸海将参与毛毛伙伴的增资计划，投资金额达1500万元人民币。\n此次增资认购体现了丽珠集团在医药健康领域的战略布局深化，通过资本运作加强产业链协同效应。新友贸海作为投资主体，此次行动有望为毛毛伙伴的业务拓展提供资金支持，同时为丽珠集团带来新的增长点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000513","BK0187","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2593959473","title":"丽珠集团(000513.SZ)：莱康奇塔单抗注射液上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593959473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593959473?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:23","pubTimestamp":1766568186,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团 发布公告，近日，公司控股子公司珠海市丽珠单抗生物技术有限公司收到国家药品监督管理局核准签发的《受理通知书》，丽珠单抗与北京鑫康合生物医药科技有限公司联合开发的“ 莱康奇塔单抗注射液”的境内生产药品注册上市许可申请获国家药监局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠集团(000513.SZ)：莱康奇塔单抗注射液上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","000513","BK0187","BK0188","BK0239"],"gpt_icon":0},{"id":"1191528112","title":"丽珠集团 - 乐卡奴单抗注射液的上市许可申请已获中国Nmpa接受审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1191528112","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191528112?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:17","pubTimestamp":1766567840,"startTime":"0","endTime":"0","summary":"丽珠集团 - 乐卡奴单抗注射液的上市许可申请已获中国Nmpa接受审查","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","BK0187","000513","BK0239"],"gpt_icon":0},{"id":"2593485215","title":"丽珠集团（000513）披露获得药物临床试验批准通知书，12月22日股价下跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485215?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:53","pubTimestamp":1766397180,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，丽珠集团报收于34.88元，较前一交易日下跌0.14%，最新总市值为315.35亿元。该股当日开盘35.0元，最高35.04元，最低34.83元，成交额达1.27亿元，换手率为0.62%。公司近日发布公告称，其全资子公司丽珠集团丽珠制药厂收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意NS-041片新增适应症“治疗抑郁症”开展临床试验。截至公告日，累计研发投入约5,853.94万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0239","BK0187","BK0028"],"gpt_icon":0},{"id":"2593560121","title":"丽珠集团最新公告：子公司NS-041片新增适应症获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2593560121","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593560121?lang=zh_cn&edition=full","pubTime":"2025-12-21 17:30","pubTimestamp":1766309425,"startTime":"0","endTime":"0","summary":"丽珠集团公告称，公司全资控股子公司丽珠集团丽珠制药厂收到国家药品监督管理局核准签发的关于NS-041片新增针对“治疗抑郁症”适应症的《药物临床试验批准通知书》。NS-041片是一款新型高选择性KCNQ2/3激动剂，目前国内唯一获批同时开展癫痫和抑郁症临床研究的KCNQ2/3激动剂。截至公告披露日，NS-041片累计直接投入的研发费用约为人民币5,853.94万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122100006189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","000513","BK0187","BK0188"],"gpt_icon":0},{"id":"2589339803","title":"丽珠集团（000513）披露调整与丽珠单抗2025年度持续关连交易预计，12月8日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339803","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339803?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:48","pubTimestamp":1765187300,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，丽珠集团报收于35.75元，较前一交易日下跌0.08%，最新总市值为323.22亿元。该股当日开盘35.79元，最高35.95元，最低35.67元，成交额达1.78亿元，换手率为0.85%。近日，丽珠医药集团股份有限公司发布第十一届董事会第二十九次会议决议公告。会议同意调整与控股子公司丽珠单抗2025年度持续关连交易预计金额至人民币16,600万元，新增金额为3,760万元。公司已就新增关连交易签订补充协议。表决结果为同意7票，反对0票，弃权0票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000513","BK0028","BK0187","BK0188"],"gpt_icon":0},{"id":"2589338309","title":"丽珠集团(000513.SZ)：公司2025年共有194个产品纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338309","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338309?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:04","pubTimestamp":1765181042,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团(000513.SZ)公告，关于公司产品纳入国家医保目录的情况，2025年集团共有194个产品纳入《国家医保目录》，含甲类92个、乙类102个。其中：注射用阿立哌唑微球通过谈判首次纳入国家医保目录，注射用醋酸曲普瑞林微球新增适应症，注射用艾普拉唑钠续约成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0187","BK0239","BK0028","000513"],"gpt_icon":0},{"id":"2588581775","title":"丽珠集团（000513）披露关于回购公司股份的进展公告，12月01日股价上涨1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588581775","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588581775?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:19","pubTimestamp":1764598783,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，丽珠集团报收于35.99元，较前一交易日上涨1.24%，最新总市值为325.39亿元。该股当日开盘35.51元，最高36.0元，最低35.42元，成交额达1.87亿元，换手率为0.89%。近日，丽珠集团发布关于回购公司股份的进展公告。公告显示，丽珠医药集团股份有限公司于2024年12月24日和2025年5月29日分别召开股东大会，审议通过回购部分A股股份方案及继续实施回购A股股份方案，并授予董事会回购H股的一般授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100036608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","000513","BK0188","BK0187"],"gpt_icon":0},{"id":"2588874719","title":"【机构调研记录】易米基金调研丽珠集团、众生药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588874719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588874719?lang=zh_cn&edition=full","pubTime":"2025-12-01 08:02","pubTimestamp":1764547333,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月28日披露的机构调研信息，易米基金近期对2家上市公司进行了调研，相关名单如下：1）丽珠集团 调研纪要：LZM012银屑病适应症计划下月递交上市申请，已获CDE优先审评确认，强直适应症预计明年上半年申报。旗下最近一年表现最佳的公募基金产品为易米低碳经济股票发起A，最新单位净值为1.13，近一年增长45.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100000276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0187","000513","BK0028","BK0188","BK0077"],"gpt_icon":0},{"id":"2583514906","title":"每周股票复盘：丽珠集团（000513）拟变更独立董事并召开临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514906","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583514906?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:52","pubTimestamp":1763236334,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，丽珠集团报收于37.6元，较上周的37.41元上涨0.51%。本周关注点公司公告汇总：丽珠集团提名王智瑶为独立董事候选人，将召开临时股东大会审议相关议案。该提名尚需提交股东大会审议，并经深圳证券交易所备案审核无异议后方可表决。近日，公司收到通知，王智瑶女士已完成线上独立董事任前培训，并取得深圳证券交易所认可的培训证明，其任职资格和独立性已通过深交所备案审核无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0188","BK0239","BK0028","000513"],"gpt_icon":0},{"id":"2583359919","title":"丽珠集团（000513）披露独立董事候选人取得独立董事培训证明，11月13日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583359919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583359919?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:31","pubTimestamp":1763044263,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，丽珠医药集团股份有限公司于2025年11月10日召开第十一届董事会第二十八次会议，提名王智瑶女士为公司独立董事候选人，该事项尚需提交股东大会审议。截至2025年第一次临时股东大会通知发出之日，王智瑶女士尚未取得独立董事培训证明，但已承诺参加最近一次任前培训。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0239","BK0187","BK0188","BK0028"],"gpt_icon":0},{"id":"2582773668","title":"丽珠集团（000513）披露拟取消监事会并修订公司章程，11月10日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582773668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582773668?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:19","pubTimestamp":1762784383,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，丽珠集团报收于37.52元，较前一交易日上涨0.29%，最新总市值为339.22亿元。该股当日开盘37.33元，最高37.54元，最低37.07元，成交额达2.9亿元，换手率为1.33%。近日，丽珠集团发布关于召开2025年第一次临时股东大会的通知，公司将于2025年12月10日召开2025年第一次临时股东大会，会议由董事会召集，现场会议地点位于广东省珠海市金湾区创业北路38号丽珠工业园总部大楼六楼会议室。股权登记日为2025年12月3日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK0188","BK0028","000513"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770795586367,"stockEarnings":[{"period":"1week","weight":0.0169},{"period":"1month","weight":-0.0271},{"period":"3month","weight":-0.0514},{"period":"6month","weight":-0.1024},{"period":"1year","weight":0.005},{"period":"ytd","weight":0.0328}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0019},{"period":"3month","weight":0.0321},{"period":"6month","weight":0.126},{"period":"1year","weight":0.2427},{"period":"ytd","weight":0.0402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47343人(较上一季度增加1.97%)","perCapita":"11996股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"88790万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是消化道产品、促性激素产品、精神产品、抗感染及其他产品、原料药及中间体产品、中药制剂产品、生物制品、诊断试剂及设备产品、其他。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}